LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2014

Dec 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2014-12-10

Reporting Person: Invus C.V. (Director, 10% Owner)
Reporting Person: Ulys, L.L.C. (Director, 10% Owner)
Reporting Person: DEBBANE RAYMOND (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-12-10	Common Stock	P	315896	$0.9033	Acquired	30098505	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	34685	Direct

Footnotes

F1: These securities are directly held by Invus C.V.

F2: These securities are directly held by Mr. Raymond Debbane.

F3: Ulys, L.L.C. is the general partner of Invus C.V., and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.

F4: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F5: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.8946 to $0.9093, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.